100% prepayment by SWIFT or Stripe. Larger orders quoted by volume; freight quoted on request
Functional ingredient·
NAD+ precursor
·Japan

Beta-Nicotinamide Mononucleotide (NMN) Powder 99%

Beta-nicotinamide mononucleotide powder, not less than 99% NMN by HPLC, with no carrier or excipient. Imported raw material is milled, sieved and packed in Japan and released against a written specification with a lot CoA. A raw material for capsule, tablet and powder formats in the NAD+ precursor category. MOQ 1 kg.

1 kg
Minimum order
900 USD/kg
MOQ price
20 g
Free sample
Ships from Japan 1-1.5 weeks after paymentFreight quoted on requestSWIFT or Stripe
Beta-Nicotinamide Mononucleotide (NMN) Powder 99%
Specification · lot CoA

Key figures at a glance

Your lot's CoA governs
NMN content
min. 99%
HPLC
Moisture
max. 3.0%
Karl Fischer
Heavy metals
max. 10 ppm
ICP-MS
Arsenic
max. 0.5 ppm
ICP-MS
Total plate count
max. 1,000 CFU/g
USP <61>
Coliforms
negative
USP <62>
Lot-specific values are measured and reported for every lot. Natural raw materials move with season and harvest, so we give you the figures of the lot you actually receive, not one fixed number.
What it is
100% beta-nicotinamide mononucleotide (NMN), the phosphorylated form of nicotinamide riboside and a direct precursor of NAD+. Single-ingredient powder, no carrier, no excipient. Allergen statement: none known
Form
White to pale yellow powder. Bulk density 0.5 g/ml or more (reference value). Milled and sieved in Japan for even particle size in tableting and encapsulation
Shelf life
2 years from date of manufacture, unopened. Store in a cool, dry place away from light and moisture
Packing
Lead time
Ships from Japan 1-1.5 weeks after payment. Lot CoA with every shipment
Terms
100% prepayment by SWIFT or Stripe. Larger orders quoted by volume; freight quoted on request
Price and documents

Request a price, specification or sample

Tell us what you are developing and which documents you need. We reply from Japan within one working day with the product specification, SDS and the CoA of the current lot.

Free sample for registered companies developing a product
Volume quotation for orders above the minimum
Specification, SDS and lot CoA on request

Request a sample or quotation

All fields required. Business email only.
Process

How it is made

This NMN is not synthesised in Japan. The documented Japanese part of the process starts with imported NMN raw material and covers milling, sieving, packing and release testing. We state this openly because origin is the first question a regulatory team asks about NMN, and the answer should come from the supplier documents, not from the sales page.

Why mill and sieve at all? The producer's specification gives one reason: the imported raw powder is processed in Japan to make it easier to tablet. A controlled particle size and a bulk density of 0.5 g/ml or more (reference value) are what the formulator receives.

Raw material intake

Step 1 · imported NMN

Beta-nicotinamide mononucleotide raw powder is received from abroad for processing in Japan

Milling

Step 2 · crushing

Raw powder is milled to break agglomerates

Sieving

Step 3 · classification

Milled powder is sieved to a uniform particle size for tableting and encapsulation

Packing

Step 4 · packing in Japan

Sieved powder is packed and labelled; packing format confirmed with the quotation

Release testing

Step 5 · per specification

NMN content by HPLC, moisture by Karl Fischer, heavy metals and arsenic by ICP-MS, total plate count and coliforms by USP <61> and <62>

Lot documentation

Step 6 · CoA

A Certificate of Analysis for the lot you receive travels with the goods; specification and SDS on request before you order

Specification

Specification at a glance

The grade on this page. Other grades, where available, are specified on request.

Identity and composition

  • Product name: Beta-Nicotinamide Mononucleotide (NMN) powder
  • Ingredients: 100% beta-nicotinamide mononucleotide; no carrier, no excipient
  • Isomer: beta form, the biologically active isomer used in NAD+ precursor research
  • Appearance: white to pale yellow powder, visual inspection
  • Allergen statement: none known
  • Country of origin (processing): Japan; imported raw material milled, sieved and packed in Japan
  • Halal / kosher certificates: not held

Process and peptide profile

  • Process in Japan: imported raw powder, milling, sieving, packing
  • Purpose of processing: uniform particle size for tableting, per the producer's specification
  • Bulk density: 0.5 g/ml or more, reference value
  • Molecule: NMN is a mononucleotide of nicotinamide; in the cell it is converted to NAD+ by NMNAT enzymes (general biochemistry, not a product claim)

Analytical specification

  • NMN content: not less than 99%, HPLC
  • Moisture: not more than 3.0%, Karl Fischer method
  • Bulk density: 0.5 g/ml or more, reference value

Contaminants, microbiology and safety

  • Heavy metals (total): not more than 10 ppm, ICP-MS
  • Arsenic: not more than 0.5 ppm, ICP-MS
  • Total plate count: not more than 1,000 CFU/g, USP <61>
  • Coliforms: negative, USP <62>
  • Lot CoA: measured values for the parameters above are reported for every lot

Shelf life, storage and packing

  • Shelf life: 2 years from date of manufacture, unopened
  • Storage: cool, dry place, away from light and moisture; NMN is moisture-sensitive, keep the pack sealed after opening
  • MOQ: 1 kg
  • Packing: confirmed with the quotation
  • Lead time: ships from Japan 1-1.5 weeks after payment; freight quoted on request
  • Documents: specification, SDS and lot CoA; CoA ships with the goods
SPEC
Product specification, PDF. On request through the form.
CoA
Certificate of Analysis. One for every lot, ships with the goods.
SDS
Safety Data Sheet. On request through the form.

Example lot values are published in the developer's guide below. They are an example, not a specification; your lot's CoA governs.

Direct from Japan

Working with us

A Japanese trading company selling directly to brand owners and contract manufacturers. No distributor layer between you and the documents.

A CoA for the lot you receive

Every shipment travels with the Certificate of Analysis of its own lot, with the measured values and the full safety panel.

Start at the minimum order

A small first order lets you run a pilot batch before committing to bulk. Larger volumes are quoted by volume and delivery terms.

Free sample

For registered companies developing a product. Tell us the format you plan and we will say honestly what to expect.

Ships from Japan in 1-1.5 weeks

After payment is received. Freight quoted on request. Specification and SDS before you order, CoA with the goods.

Buyer's checklist

What to ask any supplier

If you are comparing ingredients for a new SKU, these questions separate one material from another quickly.

Is NMN permitted as a food or supplement ingredient in my market, and under what condition?

NMN status differs by market and has changed recently (US, EU, Australia). The buyer holds the market authorisation; we supply the documents. See the developer's guide below for the current picture and dates.

Which purity method is behind the 99% figure, and what does the lot CoA show?

Ask for the HPLC result of the actual lot, not the specification limit. Our lot CoA reports NMN content, moisture, heavy metals, arsenic, total plate count and coliforms.

Where is the raw material made, and what is done in Japan?

For this product the raw NMN is imported and milled, sieved and packed in Japan. If your dossier needs the country of synthesis, request it before ordering.

How will the powder behave in my process?

Bulk density is given as a reference value of 0.5 g/ml or more; NMN is moisture-sensitive (moisture limit 3.0%). Run a small-batch trial for flow, compression and capsule fill before committing to bulk.

What daily dose will my label carry, and is it inside the local frame?

Human studies have used 100 to 1,250 mg per day in different designs; regulators set their own frames (for example 300 mg per day in the EFSA opinion of May 2026). The label dose is the brand's regulatory decision, not a product property.

For product developers

The developer's guide

What each component is, what the processing changes, and what published research on the raw material has examined. No health claims; references on request.

Where this ingredient fits

NMN sits in the NAD+ precursor category together with nicotinamide riboside and niacinamide. Brands buy it for capsule, tablet and stick-pack products positioned around healthy aging, cellular energy metabolism and longevity, and for combination formulas with resveratrol, collagen peptides or probiotics. The grade on this page is a single-ingredient powder at 99% or more NMN, so the formulator controls the dose and the excipients.

Formats we have supplied or quoted

  • Bulk powder for in-house encapsulation and tableting, from 1 kg
  • Finished hard capsules at 150 mg NMN per capsule in pouch packs, produced on request as an OEM white-label product
  • Combination capsules with resveratrol and lactobacillus as an OEM concept

OEM finished-product manufacturing runs at our own Tomioka Plant in Gunma. Tell us the format and the target dose and we quote the bulk powder and the finished product side by side.

What you receive

A written specification, an SDS and the Certificate of Analysis of your lot. The specification parameters are NMN content by HPLC, moisture by Karl Fischer, heavy metals and arsenic by ICP-MS, total plate count and coliforms by USP methods. Shelf life is 2 years unopened in cool, dry storage away from light.

Related ingredients

For longevity and metabolic concepts buyers often pair NMN with nattokinase or fish collagen tripeptide from the same catalogue.

The developer's guide to NMN

What NMN is

Beta-nicotinamide mononucleotide is a nucleotide built from nicotinamide (a form of vitamin B3), ribose and one phosphate group. In human cells it is one step away from NAD+ (nicotinamide adenine dinucleotide): the enzymes NMNAT1-3 attach an adenosine monophosphate to NMN to form NAD+. NAD+ is a coenzyme in redox reactions of energy metabolism and a substrate for sirtuins and PARP enzymes. This is textbook biochemistry and describes the molecule, not an effect of our product.

What human studies have examined

Published human trials on oral NMN as a molecule, listed by design so that your regulatory team can read the originals. These are not claims about our product.

  • Single oral doses of 100, 250 and 500 mg in 10 healthy men; safety parameters and NMN metabolites in plasma measured over 5 hours. Endocrine Journal 2020, DOI 10.1507/endocrj.EJ19-0313.
  • 1,250 mg once daily for 4 weeks in 31 healthy adults, randomised, double-blind, placebo-controlled; the authors evaluated safety and tolerability. Scientific Reports 2022, DOI 10.1038/s41598-022-18272-y.
  • 300, 600 or 900 mg once daily for 60 days in 80 healthy middle-aged adults, randomised, multicentre, placebo-controlled; the primary endpoint was blood NAD concentration by dose. GeroScience 2023, DOI 10.1007/s11357-022-00705-1.
  • 250 mg per day (125 mg twice daily) for 12 weeks in 36 healthy middle-aged adults, randomised, double-blind, placebo-controlled; NAD metabolites in serum and arterial stiffness were measured. Scientific Reports 2023, DOI 10.1038/s41598-023-29787-3.

Across these designs the authors report that oral NMN was tolerated at the doses tested and that blood NAD metabolites rose with intake. Whether any of this can be stated on a finished product depends on the claims rules of the market of sale.

Regulatory picture, as of October 2026

  • United States. In December 2025 the FDA reversed its 2022 position and acknowledged NMN as a new dietary ingredient, with two NDI notifications on record. A brand needs coverage by a recognised NDIN for its NMN source. Source: FDA NDI process pages, checked July 2026.
  • European Union. NMN is a novel food. EFSA published a positive safety opinion in May 2026 on one applicant's NMN at 300 mg per day for the general population, excluding pregnant and lactating women. Union-list authorisation follows a Commission and Member State review and was pending at the time of writing.
  • Australia. NMN is a permissible ingredient for listed medicines with sponsor-specific conditions; check the current TGA Permissible Ingredients Determination.
  • Other markets. Status differs; the buyer confirms admission before ordering. We supply specification, SDS and lot CoA for the dossier.

Handling notes for formulators

NMN is hygroscopic and the specification caps moisture at 3.0%. Keep bulk packs sealed, weigh in a dry room and consider moisture-barrier primary packaging for finished products. The powder has no carrier, so capsule fill weight and tablet formulation are entirely yours to design.

FAQ

Before you order

What purity is this NMN and how is it tested?

Not less than 99% beta-nicotinamide mononucleotide by HPLC. Each lot ships with a Certificate of Analysis that reports the measured NMN content together with moisture (Karl Fischer, max. 3.0%), heavy metals (max. 10 ppm), arsenic (max. 0.5 ppm), total plate count (max. 1,000 CFU/g) and coliforms (negative).

Is the NMN made in Japan?

The raw NMN powder is imported and then milled, sieved and packed in Japan; the specification lists Japan as the country of origin of the finished ingredient. If your dossier requires the country of synthesis of the raw material, request it from us before ordering and we confirm it in writing.

What are the MOQ, price and lead time?

MOQ is 1 kg at 900 USD/kg; larger orders are quoted by volume. Payment is 100% prepayment by SWIFT or Stripe. Goods ship from Japan 1-1.5 weeks after payment; freight is quoted on request. Specification and SDS are available before you order, the lot CoA ships with the goods.

Can I sell NMN in my market?

That depends on the market and the status changes. In the United States the FDA acknowledged NMN as a new dietary ingredient in December 2025, subject to NDIN coverage. In the EU NMN is a novel food; EFSA gave a positive safety opinion in May 2026 and authorisation was pending at the time of writing. In Australia it is a permissible ingredient with sponsor conditions. The buyer confirms admission; we supply the documents.

Can you make the finished product instead of selling the powder?

Yes. We have supplied NMN as hard capsules at 150 mg per capsule in pouch packs as an OEM white-label product, and quoted combination capsules with resveratrol and lactobacillus. Finished products are made at our Tomioka Plant in Gunma. Send the format and the target dose and we quote the powder and the finished product together.
Beta-Nicotinamide Mononucleotide (NMN) Powder 99%

Ready to run a first batch?

Start at the minimum order. Free sample. Specification, SDS and lot CoA on request.

Request a sample or quotation
900 USD/kg
at MOQ · free sample
Request a sample

Beta-Nicotinamide Mononucleotide (NMN) Powder 99%

Beta-nicotinamide mononucleotide powder, not less than 99% NMN by HPLC, with no carrier or excipient. Imported raw material is milled, sieved and packed in Japan and released against a written specification with a lot CoA. A raw material for capsule, tablet and powder formats in the NAD+ precursor category. MOQ 1 kg.
Request specs
CATEGORY
NAD+ precursor
MOQ
1 kg
MOQ price
900 USD/kg

Where this ingredient fits

NMN sits in the NAD+ precursor category together with nicotinamide riboside and niacinamide. Brands buy it for capsule, tablet and stick-pack products positioned around healthy aging, cellular energy metabolism and longevity, and for combination formulas with resveratrol, collagen peptides or probiotics. The grade on this page is a single-ingredient powder at 99% or more NMN, so the formulator controls the dose and the excipients.

Formats we have supplied or quoted

  • Bulk powder for in-house encapsulation and tableting, from 1 kg
  • Finished hard capsules at 150 mg NMN per capsule in pouch packs, produced on request as an OEM white-label product
  • Combination capsules with resveratrol and lactobacillus as an OEM concept

OEM finished-product manufacturing runs at our own Tomioka Plant in Gunma. Tell us the format and the target dose and we quote the bulk powder and the finished product side by side.

What you receive

A written specification, an SDS and the Certificate of Analysis of your lot. The specification parameters are NMN content by HPLC, moisture by Karl Fischer, heavy metals and arsenic by ICP-MS, total plate count and coliforms by USP methods. Shelf life is 2 years unopened in cool, dry storage away from light.

Related ingredients

For longevity and metabolic concepts buyers often pair NMN with nattokinase or fish collagen tripeptide from the same catalogue.

Price and documents

Request a price, specification or sample

The developer's guide to NMN

What NMN is

Beta-nicotinamide mononucleotide is a nucleotide built from nicotinamide (a form of vitamin B3), ribose and one phosphate group. In human cells it is one step away from NAD+ (nicotinamide adenine dinucleotide): the enzymes NMNAT1-3 attach an adenosine monophosphate to NMN to form NAD+. NAD+ is a coenzyme in redox reactions of energy metabolism and a substrate for sirtuins and PARP enzymes. This is textbook biochemistry and describes the molecule, not an effect of our product.

What human studies have examined

Published human trials on oral NMN as a molecule, listed by design so that your regulatory team can read the originals. These are not claims about our product.

  • Single oral doses of 100, 250 and 500 mg in 10 healthy men; safety parameters and NMN metabolites in plasma measured over 5 hours. Endocrine Journal 2020, DOI 10.1507/endocrj.EJ19-0313.
  • 1,250 mg once daily for 4 weeks in 31 healthy adults, randomised, double-blind, placebo-controlled; the authors evaluated safety and tolerability. Scientific Reports 2022, DOI 10.1038/s41598-022-18272-y.
  • 300, 600 or 900 mg once daily for 60 days in 80 healthy middle-aged adults, randomised, multicentre, placebo-controlled; the primary endpoint was blood NAD concentration by dose. GeroScience 2023, DOI 10.1007/s11357-022-00705-1.
  • 250 mg per day (125 mg twice daily) for 12 weeks in 36 healthy middle-aged adults, randomised, double-blind, placebo-controlled; NAD metabolites in serum and arterial stiffness were measured. Scientific Reports 2023, DOI 10.1038/s41598-023-29787-3.

Across these designs the authors report that oral NMN was tolerated at the doses tested and that blood NAD metabolites rose with intake. Whether any of this can be stated on a finished product depends on the claims rules of the market of sale.

Regulatory picture, as of October 2026

  • United States. In December 2025 the FDA reversed its 2022 position and acknowledged NMN as a new dietary ingredient, with two NDI notifications on record. A brand needs coverage by a recognised NDIN for its NMN source. Source: FDA NDI process pages, checked July 2026.
  • European Union. NMN is a novel food. EFSA published a positive safety opinion in May 2026 on one applicant's NMN at 300 mg per day for the general population, excluding pregnant and lactating women. Union-list authorisation follows a Commission and Member State review and was pending at the time of writing.
  • Australia. NMN is a permissible ingredient for listed medicines with sponsor-specific conditions; check the current TGA Permissible Ingredients Determination.
  • Other markets. Status differs; the buyer confirms admission before ordering. We supply specification, SDS and lot CoA for the dossier.

Handling notes for formulators

NMN is hygroscopic and the specification caps moisture at 3.0%. Keep bulk packs sealed, weigh in a dry room and consider moisture-barrier primary packaging for finished products. The powder has no carrier, so capsule fill weight and tablet formulation are entirely yours to design.

Beta-Nicotinamide Mononucleotide (NMN) Powder 99%
Got Questions? We've Got Answers

Frequently Asked Questions

  • What purity is this NMN and how is it tested?

    Not less than 99% beta-nicotinamide mononucleotide by HPLC. Each lot ships with a Certificate of Analysis that reports the measured NMN content together with moisture (Karl Fischer, max. 3.0%), heavy metals (max. 10 ppm), arsenic (max. 0.5 ppm), total plate count (max. 1,000 CFU/g) and coliforms (negative).

  • Is the NMN made in Japan?

    The raw NMN powder is imported and then milled, sieved and packed in Japan; the specification lists Japan as the country of origin of the finished ingredient. If your dossier requires the country of synthesis of the raw material, request it from us before ordering and we confirm it in writing.

  • What are the MOQ, price and lead time?

    MOQ is 1 kg at 900 USD/kg; larger orders are quoted by volume. Payment is 100% prepayment by SWIFT or Stripe. Goods ship from Japan 1-1.5 weeks after payment; freight is quoted on request. Specification and SDS are available before you order, the lot CoA ships with the goods.

  • Can I sell NMN in my market?

    That depends on the market and the status changes. In the United States the FDA acknowledged NMN as a new dietary ingredient in December 2025, subject to NDIN coverage. In the EU NMN is a novel food; EFSA gave a positive safety opinion in May 2026 and authorisation was pending at the time of writing. In Australia it is a permissible ingredient with sponsor conditions. The buyer confirms admission; we supply the documents.

SAMPLES

Try Before You Buy